Sequence 7 from Patent US 20030077289

General Information


DRACP ID  DRACP01230

Peptide Name   Sequence 7 from Patent US 20030077289

Sequence  AAVALLPAVLLALLAP

Sequence Length  16

UniProt ID  P08620 

PubChem CID  Not available

Origin  Human

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01230

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C74H130N16O17

Absent amino acids  CDEFGHIKMNQRSTWY

Common amino acids  AL

Mass  178372

Pl  6.11

Basic residues  0

Acidic residues  0

Hydrophobic residues  14

Net charge  0

Boman Index  4846

Hydrophobicity  242.5

Aliphatic Index  220

Half Life 
  Mammalian: 100 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2003/0077289 A1

Patent Title  Use of cell-penetrating peptides to generate antitumor immunity.

Other Iinformation  Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status: Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority: Feb 15, 2001

Other Published ID  CN1309417C  CN1503628A  WO2002064057A2  WO2002064057A3 




DRACP is developed by Dr.Zheng's team.